These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12100223)

  • 1. The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects.
    Tfelt-Hansen P; Seidelin K; Stepanavage M; Lines C
    Br J Clin Pharmacol; 2002 Jul; 54(1):38-44. PubMed ID: 12100223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.
    Christie S; Göbel H; Mateos V; Allen C; Vrijens F; Shivaprakash M;
    Eur Neurol; 2003; 49(1):20-9. PubMed ID: 12464714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy.
    Láinez MJ; Galván J; Heras J; Vila C
    Eur J Neurol; 2007 Mar; 14(3):269-75. PubMed ID: 17355546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches.
    de Hoon JN; Willigers JM; Troost J; Struijker-Boudier HA; Van Bortel LM
    Clin Pharmacol Ther; 2000 Oct; 68(4):418-26. PubMed ID: 11061582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers.
    Shadle CR; Liu G; Goldberg MR
    J Clin Pharmacol; 2000 Mar; 40(3):309-15. PubMed ID: 10709161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers.
    Dixon RM; Meire HB; Evans DH; Watt H; On N; Posner J; Rolan PE
    Cephalalgia; 1997 Oct; 17(6):639-46. PubMed ID: 9350383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group.
    Ahrens SP; Farmer MV; Williams DL; Willoughby E; Jiang K; Block GA; Visser WH
    Cephalalgia; 1999 Jun; 19(5):525-30. PubMed ID: 10403069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine.
    Bomhof M; Paz J; Legg N; Allen C; Vandormael K; Patel K
    Eur Neurol; 1999; 42(3):173-9. PubMed ID: 10529545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.
    Zhang L; Hay JW
    CNS Drugs; 2005; 19(7):635-42. PubMed ID: 15984898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study.
    Krymchantowski AV; Filho PF; Bigal ME
    Cephalalgia; 2006 Jul; 26(7):871-4. PubMed ID: 16776704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine.
    Gijsman H; Kramer MS; Sargent J; Tuchman M; Matzura-Wolfe D; Polis A; Teall J; Block G; Ferrari MD
    Cephalalgia; 1997 Oct; 17(6):647-51. PubMed ID: 9350384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study.
    Krymchantowski AV; Barbosa JS
    Cephalalgia; 2002 May; 22(4):309-12. PubMed ID: 12100094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects.
    Goldberg MR; Lee Y; Vyas KP; Slaughter DE; Panebianco D; Ermlich SJ; Shadle CR; Brucker MJ; McLoughlin DA; Olah TV
    J Clin Pharmacol; 2000 Jan; 40(1):74-83. PubMed ID: 10631625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.
    Seeburger JL; Taylor FR; Friedman D; Newman L; Ge Y; Zhang Y; Hustad CM; Lasorda J; Fan X; Hewitt D; Ho T; Connor KM
    Cephalalgia; 2011 May; 31(7):786-96. PubMed ID: 21078681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve.
    Tfelt-Hansen P; Eickhoff JH; Olesen J
    Acta Pharmacol Toxicol (Copenh); 1980 Aug; 47(2):151-6. PubMed ID: 7435199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group.
    Pascual J; Vega P; Diener HC; Allen C; Vrijens F; Patel K
    Cephalalgia; 2000 Jun; 20(5):455-61. PubMed ID: 11037741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of rizatriptan in migraine attacks in children.
    Ahonen K; Hämäläinen ML; Eerola M; Hoppu K
    Neurology; 2006 Oct; 67(7):1135-40. PubMed ID: 16943370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine.
    Goldberg MR; Lowry RC; Musson DG; Birk KL; Fisher A; De Puy ME; Shadle CR
    J Clin Pharmacol; 1999 Feb; 39(2):192-9. PubMed ID: 11563413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary side-effect potential of current and prospective antimigraine drugs.
    MaassenVanDenBrink A; Reekers M; Bax WA; Ferrari MD; Saxena PR
    Circulation; 1998 Jul; 98(1):25-30. PubMed ID: 9665056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
    Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
    Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.